Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kos Settlement Keeps Barr’s Generic Niaspan, Advicor Off Market Until 2013

This article was originally published in The Pink Sheet Daily

Executive Summary

The generic firm’s decision to settle appears to have been influenced by a federal appeals court’s recent decision to rescind an earlier ruling on “public use” and patent invalidity in the Paxil case. Barr could enter the market before 2013 if another ANDA product launches.

You may also be interested in...



Zyprexa Patent Verdict Coming April 14

Timing of the Indianapolis court's verdict suggests the outcome could be favorable for Lilly. The announcement comes a week after a federal appeals court rescinded a ruling on a Paxil patent that could have aided generic companies' challenges to the olanzapine patent.

Barr To Co-Promote Kos' Anti-Cholesterol Products Under Settlement

Barr's patent litigation settlement with Kos includes a co-promotion agreement for the brand firm's cholesterol-lowering products Niaspan and Advicor

Barr To Co-Promote Kos' Anti-Cholesterol Products Under Settlement

Barr's patent litigation settlement with Kos includes a co-promotion agreement for the brand firm's cholesterol-lowering products Niaspan and Advicor

Related Content

Topics

UsernamePublicRestriction

Register

PS061979

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel